Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes.

Abstract : We determined the number and functional status of CD4+ CD25(high) regulatory T cells (Treg) in blood samples from patients with metastatic carcinoma, and evaluated their sensitivity to a single intravenous infusion of cyclophosphamide. Treg numbers were significantly higher in 49 patients with metastatic cancer (9.2% of CD4+ T cells) compared to 24 healthy donors (7.1%). These cells expressed the transcription factor forkhead box P3 (FoxP3), glucocorticoid-induced tumour necrosis factor receptor family-related protein (GITR) and intracellular CD152, and demonstrated a suppressive activity in vitro against CD4+ CD25- autologous proliferation. At a single intravenous infusion, cyclophosphamide failed, in association with a non-specific immunotherapy by intratumoral bacille Calmette-Guérin (BCG), to modulate significantly Treg numbers or function. Metastatic cancer is associated with an expansion of peripheral blood CD4+ CD25(high) FoxP3+ GITR+ CD152+ Treg cells whose immunosuppressive properties do not differ from those of healthy subjects. Moreover, cyclophosphamide administration may not represent an optimal therapy to eliminate Treg, which further underlines the need to identify specific agents that would selectively deplete these cells.
Type de document :
Article dans une revue
Clinical and Experimental Immunology, Wiley, 2007, 150 (3), pp.523-30. 〈10.1111/j.1365-2249.2007.03521.x〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00479739
Contributeur : Philippe Saas <>
Soumis le : dimanche 2 mai 2010 - 14:28:06
Dernière modification le : lundi 9 juillet 2018 - 13:12:02

Lien texte intégral

Identifiants

Citation

S. Audia, A. Nicolas, D. Cathelin, N. Larmonier, Christophe Ferrand, et al.. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes.. Clinical and Experimental Immunology, Wiley, 2007, 150 (3), pp.523-30. 〈10.1111/j.1365-2249.2007.03521.x〉. 〈inserm-00479739〉

Partager

Métriques

Consultations de la notice

107